ADIL News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AD

Mkt Cap

$10.2M

Volume

56.36K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Adial Pharmaceuticals granted 155,446 stock options to a new employee at an exercise price of $4.22 per share as an inducement to employment. The options vest over four years and have a ten-year term. The grant was made under Nasdaq Listing Rule 5635(c)(4). Following its June 2026 acquisition of Azora Therapeutics, Adial has shifted focus to treating inflammatory diseases, with AT177 as its lead program for ulcerative colitis treatment, currently in IND-enabling studies with an IND filing planned for H1 2027.GlobeNewswire Inc. · Sep 30, 2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million FinancingAdial Pharmaceuticals acquired Azora Therapeutics and secured up to $64 million in financing to advance AT177, a colon-targeted AhR agonist for ulcerative colitis treatment. The deal includes $32 million upfront and potential $32 million in milestone-based funding, with Phase 1 clinical trials planned for mid-2027. The company also appointed Wendy Young, Ph.D. to its Board of Directors.Benzinga · Jun 11, 2026

Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsightThe alcohol use disorder (AUD) market is projected to grow at a 12.1% CAGR from 2026-2036, driven by novel therapeutic mechanisms and new drug approvals. The market was valued at USD 1.1 billion in 2025 across seven major markets. Key emerging therapies from companies like Adial Pharmaceuticals, Eli Lilly, MediciNova, and Altimmune are expected to transform the treatment landscape, with AD04 projected to capture the largest market share by 2036, replacing current leader VIVITROL.GlobeNewswire Inc. · Jun 8, 2026

Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsightThe peripheral T-cell lymphoma (PTCL) treatment market is projected to grow at a 7% CAGR through 2036, driven by increasing disease incidence and expanding patient populations. The market was valued at USD 800 million in 2025, with the US accounting for 68% of the market. Multiple emerging therapies from major pharmaceutical companies are expected to transform the treatment landscape, with ADCETRIS currently holding the largest market share at over USD 300 million.GlobeNewswire Inc. · Apr 27, 2026

Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045Adial Pharmaceuticals announced the publication of an international patent application for AD04, its lead investigational drug for treating Alcohol Use Disorder in heavy drinking patients. The patent, once granted, is expected to protect the company's core assets through at least 2045. The patent application is based on treatment of populations identified as particularly responsive to ondansetron treatment following examination of Adial's clinical data.GlobeNewswire Inc. · Jan 14, 2026

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz ShowAdial Pharmaceuticals' CEO Cary Claiborne was featured on the Big Biz Show, discussing the company's clinical-stage biopharmaceutical work in addiction treatment, specifically highlighting their investigational drug AD04 for Alcohol Use Disorder.GlobeNewswire Inc. · Oct 17, 2025

Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsightThe substance use disorder market is expected to grow between 2025 and 2034, driven by greater awareness, the introduction of new therapies, and ongoing research and development efforts. The report covers the market assessment of Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder.GlobeNewswire Inc. · Apr 28, 2025

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04Adial Pharmaceuticals received positive feedback from the FDA on its proposed in vitro bridging strategy for its drug candidate AD04, a key step towards advancing the drug into Phase 3 clinical trials for the treatment of alcohol use disorder.GlobeNewswire Inc. · Feb 25, 2025

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use DisorderAdial Pharmaceuticals announced positive results from a pharmacokinetics study of its investigational drug AD04 for the treatment of Alcohol Use Disorder. The study results support the planned near micro-dosing regimen and the company's plans to pursue FDA approval under the 505(b)(2) regulatory pathway.GlobeNewswire Inc. · Jan 29, 2025

Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsightThe alcohol use disorder market is expected to show positive growth, with growing awareness about AUD and reduced stigma surrounding mental health issues encouraging more individuals to seek treatment during the forecast period (2024–2034).GlobeNewswire Inc. · Dec 11, 2024

AD

ADILAdial Pharmaceuticals, Inc

ADIL

Pay with—

Available Balance0.00

Your PositionYou don't own any ADIL yet.

Related Tickers

Earnings